Vensana Capital is a venture capital investment firm that focuses on healthcare with breakthrough innovations in medical technology. The firm was founded in 2018 and is based in Minneapolis, Minnesota, United States.

Vensana Capital

Evident Vascular

Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular.

Evident Vascular is a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence (AI) technology. The company's IVUS platform is designed to facilitate superior imaging quality, improved image interpretation guidance, and streamlined clinical workflows. It aims to expand the adoption of IVUS, particularly in peripheral vascular interventions, by addressing limitations in existing IVUS platforms such as suboptimal image quality, interpretation challenges, and inefficient workflows.

Evident Vascular launches with $35m funding to develop IVUS platform

Intravascular ultrasound tech developer Evident Vascular exits stealth mode with $35M Series A

Evident Vascular, Inc.

Evident Vascular Receives Financing for IVUS Platform Development

Evident Vascular Exits Stealth with $35 Million Series A Funding to Develop Intravascular Imaging Platform

Evident Vascular Exits Stealth with $35M Series A Funding

Evident Vascular exits stealth with US$35 million Series A funding to develop intravascular imaging platform

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

Evident Vascular, Inc. is a medical technology startup developing an advanced intravascular ultrasound (IVUS) platform. The company's technology is designed initially for peripheral vascular interventions, with future capabilities for coronary procedures. Evident Vascular's platform leverages artificial intelligence to enable superior imaging, improved image interpretation, and streamlined workflows. The company aims to address limitations in existing IVUS technologies, which were primarily designed for coronary procedures and secondarily adapted for peripheral vascular applications. By focusing on peripheral vascular interventions, Evident Vascular seeks to expand the adoption of IVUS and enable improved clinical outcomes through faster and more accurate diagnosis and treatment decisions. The platform is intended to provide clinicians with enhanced clarity for diagnosing and intervening in peripheral vascular disease cases. Evident Vascular's technology aims to set a new standard in imaging quality, interpretation guidance, ease of use, and navigation of peripheral vasculature.

Evident Vascular launches with $35M for AI-enabled intravascular ultrasound

Evident Vascular Announces Scientific Advisory Board and New Board Member

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Medtech Startup Evident Vascular Makes Its Debut

Evident Vascular is a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence (AI) technology. The company's IVUS platform is designed to facilitate superior imaging quality, improved image interpretation guidance, and streamlined clinical workflows. It aims to expand the adoption of IVUS, particularly in peripheral vascular interventions, by addressing limitations in existing IVUS platforms such as suboptimal image quality, interpretation challenges, and inefficient workflows.
Evident Vascular's IVUS platform uses AI algorithms to enable enhanced imaging capabilities and user-friendly interfaces, allowing clinicians to diagnose and treat vascular diseases more accurately and efficiently. The platform is initially focused on peripheral vascular interventions, with future potential for coronary applications.
By overcoming the shortcomings of legacy IVUS systems, Evident Vascular aims to drive increased market penetration of IVUS and improve clinical outcomes through faster and more precise diagnosis and treatment decisions. The company's technology is well-positioned to support the growing utilization of IVUS in the management of peripheral vascular interventions, ensuring optimal treatment for patients with peripheral vascular disease (PVD).

<div>
 
 Clover Health is a healthcare company focused on serving Medicare Advantage members. The company leverages its proprietary software platform, the Clover Assistant, to aggregate and analyze patient data from across the healthcare ecosystem. This data-driven approach aims to support clinical decision-making and improve health outcomes for seniors.
 
 
 
 
 Clover Health operates in two segments: Insurance and Non-Insurance. Through its Insurance segment, the company provides PPO and HMO plans to Medicare Advantage members across several states. As of March 2022, Clover Health had approximately 257,000 lives under its management, a significant increase from around 66,000 lives in the first quarter of 2021.
 
 
 
 
 The Clover Assistant is a key component of Clover Health's strategy. This software platform is designed to provide physicians with relevant patient information to facilitate coordinated care. The company reported that in 2021, its Insurance members whose primary care providers (PCPs) utilized the Clover Assistant had a significantly lower medical care ratio (MCR) compared to members whose PCPs did not use the platform.
 
 
 
 
 In its Non-Insurance segment, Clover Health participates in the Centers for Medicare &amp; Medicaid Services' (CMS) Direct Contracting model, which will transition to the ACO Reach model in 2023. This segment involves aligning with Original Medicare beneficiaries through provider attribution or voluntary alignment.
 
 
 
 
 For the full year 2022, Clover Health expected total revenues to range from USD 3.0 billion to USD 3.4 billion, including projected Insurance revenue of USD 1.0 billion to USD 1.1 billion and Non-Insurance revenue of USD 2.0 billion to USD 2.3 billion. The company also anticipated an improvement in its Insurance MCR, falling within the range of 95% to 99%, driven by operational efficiencies, increased risk scores, and lower Covid-19 costs.
 
 
 
</div>

Clover Health

Digital Diagnostics is a healthcare technology company that develops artificial intelligence (AI) systems for disease diagnosis by analyzing medical images. The company's flagship product, LumineticsCore (formerly known as IDx-DR), is an FDA-cleared autonomous AI system designed to detect diabetic retinopathy and diabetic macular edema during a patient encounter without needing a physician to interpret the images. LumineticsCore increases patient access to care by providing diagnostic results at the point-of-care, eliminating the need for an additional appointment for most patients. This enables healthcare providers to close the gap in eye exams for diabetes care by offering a specialty-level diagnostic exam where the patient receives care.
Digital Diagnostics has also developed DermSpot, an AI system for detecting certain types of skin cancer, which is currently for investigational use only. The company aims to create AI diagnostic solutions that improve patient outcomes, increase healthcare productivity, and enhance accessibility and affordability of care. In April 2023, Digital Diagnostics expanded LumineticsCore to Labcorp patient service centers in Alabama.
Key customers and partnerships
In 2022, Digital Diagnostics signed a long-term strategic partnership with Baxter International to help front-line care providers deliver high-quality care and improve outcomes. The company also partnered with ArchWell Health to bring LumineticsCore to ArchWell Health centers across the US.
Additionally, Digital Diagnostics entered into a memorandum of understanding with the Kingdom of Saudi Arabia's Ministry of Investment in 2022 for international expansion.

Digital Diagnostics

Lunit is a leading provider of AI-powered solutions for cancer diagnostics and therapeutics. The company's flagship product, Lunit INSIGHT, is a suite of AI solutions for radiology that has been approved for commercial use in Europe and the UK through the MDR CE and UKCA certifications obtained in November 2022. The suite includes Lunit INSIGHT CXR for chest X-ray analysis and Lunit INSIGHT MMG for mammography analysis. Lunit INSIGHT CXR can detect 10 chest abnormalities, including pulmonary nodules and pneumothorax, with 97-99% accuracy, while Lunit INSIGHT MMG detects breast cancer with 96% accuracy.
After receiving FDA clearance, Lunit's solutions are clinically used in approximately 3,000 hospitals and medical institutions across 40 countries as of March 2024. In April 2024, a study published in European Radiology demonstrated that Lunit INSIGHT MMG could potentially reduce radiologists' workload by nearly 70% and boost cancer detection accuracy by 30.5%, showcasing its ability to enhance operational efficiency and improve patient outcomes.
In May 2024, Lunit completed the acquisition of Volpara Health Technologies, a New Zealand-based company offering software for early cancer detection, for USD 193 million. The acquisition aimed to strengthen Lunit's presence in the US market and leverage Volpara's robust repository of over 100 million medical images to develop innovative solutions for cancer diagnostics.
Key customers and partnerships
Lunit has established strategic partnerships to expand its reach and integrate its AI solutions into healthcare systems worldwide. In March 2024, the company signed supply contracts with Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore to provide Lunit INSIGHT CXR and Lunit INSIGHT MMG, respectively. These collaborations aimed to enhance lung and breast cancer detection in the East and Southeast Asian regions.
In November 2023, Lunit partnered with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore's public healthcare system through the AimSG platform, a national medical imaging AI initiative. The solution was piloted at Singapore General Hospital and Changi General Hospital, two major public hospitals, to enhance the efficiency of chest screening and provide innovative medical services with improved accuracy.
Lunit has also collaborated with leading healthcare technology companies, such as GE healthcare, Fujifilm, Philips, and Guardant Health, to deploy its AI products and leverage their distribution networks.

Lunit

Lumeon is a digital health company that provides a cloud-based Care Orchestration platform designed to automate and streamline the care coordination process for healthcare providers. The platform leverages real-time, bi-directional data integration and applies dynamic clinical intelligence to ensure that patients receive the right care at the right time, every time.
Lumeon's Care Orchestration platform acts as a "care traffic control" center, synchronizing disparate data across the care continuum, orchestrating and automating care pathway activities, and delivering relevant information to care teams and patients. By automating routine tasks and workflows, the platform enables care teams to focus on providing direct patient care, working at the top of their licenses.
The platform integrates with electronic health records (EHRs) and other systems, creating a real-time synthetic patient record to inform care decisions. It visualizes care plans, virtualizes monitoring, and automates routine tasks, ultimately reducing manual intervention and associated costs for providers. The platform can be deployed enterprise-wide and applied across various use cases within a healthcare system.
Key features of Lumeon's Care Orchestration platform include real-time bi-directional data integration with EHRs and other systems, automation of care orchestration tasks and workflows, and the ability to present information through multiple modalities, including within EHRs, native interfaces, web portals, and mobile apps.
Lumeon's platform has been deployed by leading healthcare providers in the US and Europe across more than 2,000 care locations, delivering measurable results in as little as 90 days.

Lumeon

Proscia is a software company that develops digital and computational pathology solutions. Its flagship product, Concentriq, is an enterprise pathology platform that serves as a hub for digital pathology data and AI applications. Concentriq bridges the gap between anatomic pathology laboratories and life sciences organizations, enabling real-world pathology data to fuel innovation that enhances patient care.
The platform delivers an open environment to run a range of AI applications, including Proscia's proprietary algorithms and those developed by partners or customers. One such AI solution is DermAI, a dermatopathology module launched in June 2019 to assist laboratories in tasks like case prioritization, automated quality assurance, and enhanced technical component reporting.
In February 2024, Proscia received 510(k) clearance from the FDA for its Concentriq AP-Dx solution for primary diagnosis in clinical settings. This comprehensive diagnostic software streamlines collaboration and helps drive confidence and efficiency gains. As of December 2023, over 10,000 pathologists and scientists, including those at leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies, used Proscia's solutions.
Furthermore, in December 2023, CellNetix Pathology & Laboratories announced a collaboration with Proscia to digitize a portion of its 1 million glass slides per year and adopt AI-powered digital pathology workflows.

Proscia

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

Platforms and software that generates alerts based on patient treatment and current status.

Platforms and software that monitor and track treatment plans of patients, identifies possible treatment issues, and suggests alternative treatment options.

Workflow management software that helps clinicians track and follow procedure for operations.

In most cases, CDSSs are provided to healthcare providers

Uses digital mediums to generate actionable insights from health data

Uses AI/ML to output decisions/recommended actions based on databases of medical records

Uses IoT to connect databases with medical devices for decision support

Evident Vascular, Inc. is a medical technology startup developing an advanced intravascular ultrasound (IVUS) platform. The company's technology is designed initially for peripheral vascular interventions, with future capabilities for coronary procedures. Evident Vascular's platform leverages artificial intelligence to enable superior imaging, improved image interpretation, and streamlined workflows. The company aims to address limitations in existing IVUS technologies, which were primarily designed for coronary procedures and secondarily adapted for peripheral vascular applications. By focusing on peripheral vascular interventions, Evident Vascular seeks to expand the adoption of IVUS and enable improved clinical outcomes through faster and more accurate diagnosis and treatment decisions. The platform is intended to provide clinicians with enhanced clarity for diagnosing and intervening in peripheral vascular disease cases. Evident Vascular's technology aims to set a new standard in imaging quality, interpretation guidance, ease of use, and navigation of peripheral vasculature.
Key customers and partnerships
Evident Vascular has established a Scientific Advisory Board comprising clinical experts in peripheral vascular disease procedures and technologies. The board includes notable members such as Dr. S. Jay Mathews, Director of the Cardiac Catheterization Laboratory at Manatee Memorial Hospital, and Dr. Eric A. Secemsky, Director of Vascular Intervention at Beth Israel Deaconess Medical Center. These partnerships with medical professionals are expected to provide valuable insights as the company develops its IVUS platform to meet the specific needs of interventionalists in providing optimal patient care.

Proximie is a global health technology platform that combines telepresence, augmented reality, machine learning, and artificial intelligence to enable surgeons to virtually "scrub in" to any operating room from anywhere in the world. The company's core product is a web-based software that allows surgeons to collaborate remotely by sharing live video streams of surgeries from up to four camera perspectives, along with medical scans. It features augmented reality tools that enable surgeons to draw instructions or annotations on the shared screen, providing real-time guidance during procedures.
Founded in 2016 by Dr. Nadine Hachach-Haram, a plastic surgeon, Proximie aims to democratize access to surgical expertise by connecting surgeons across the globe. Its technology helps overcome barriers caused by limited staff, time, and resources, enabling healthcare organizations to improve patient outcomes, safety, and productivity. Proximie's platform also captures data from procedures, creating a secure library that can be used for training, debriefing, and advancing surgical techniques.
As of 2023, Proximie has been used in over 13,000 surgeries across more than 500 hospitals in over 100 countries. The company has partnerships with major healthcare providers, medical device companies, and educational institutions, leveraging its technology for remote mentoring, proctoring, and accelerating the adoption of new surgical products and techniques.

Proximie

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

Evident Vascular

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless